AstraZeneca and Daiichi Sankyo’s Phase III TROPION-Lung01 study revealed that datopotamab deruxtecan (Dato-DXd), did not significantly improve overall survival in NSCLC patients

Dato-DXd, an investigational ADC, targets the TROP2 antigen, commonly overexpressed in various malignancies, including breast, colorectal, gastric, and lung cancers

The TROPION-Lung01 study showed that overall survival outcomes “numerically favored” datopotamab deruxtecan (Dato-DXd) over docetaxel, but the difference was not statistically significant

In a subset of patients with non-squamous NSCLC, Dato-DXd showed a “clinically meaningful improvement in overall survival

TROPION-Lung01 is a randomized, open-label trial involving over 600 adults with advanced or metastatic NSCLC needing systemic therapy after previous treatments